 | • レポートコード：20QY06-04964 • 出版社/出版日：QYResearch / 2020年6月3日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、142ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥576,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥864,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,152,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、癌抗体薬物コンジュゲートのグローバル市場について種類別（第一＆第二世代ADC、第三世代ADC）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・癌抗体薬物コンジュゲート市場の概要 ・世界の主要地域別癌抗体薬物コンジュゲート市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の癌抗体薬物コンジュゲート市場規模2015-2026：種類別（第一＆第二世代ADC、第三世代ADC） ・世界の癌抗体薬物コンジュゲート市場規模2015-2026：用途別（病院、クリニック、その他） ・癌抗体薬物コンジュゲートの北米市場規模2015-2020 ・癌抗体薬物コンジュゲートのヨーロッパ市場規模2015-2020 ・癌抗体薬物コンジュゲートの中国市場規模2015-2020 ・癌抗体薬物コンジュゲートの日本市場規模2015-2020 ・癌抗体薬物コンジュゲートの東南アジア市場規模2015-2020 ・癌抗体薬物コンジュゲートのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Novartis、、Merck、、Roche、、AbbVie、、UCB、、Bristol-Myers Squibb、、Stem CentRx、、Biogen Idec、、Nordic Nanovector、、Millennium、、Biotest AG、、PDL BioPharma、、Progenics Pharmaceuticals、、Seattle Genetics、、Viventia Biotechnologies、、AbGenomics Corporation、、Helix BioPharma、） ・癌抗体薬物コンジュゲートの製造コスト分析 ・販売チャネル、流通業者、顧客 ・癌抗体薬物コンジュゲートの市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Cancer Antibody Drug Conjugates Market
The global Cancer Antibody Drug Conjugates market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Cancer Antibody Drug Conjugates Scope and Market Size
The global Cancer Antibody Drug Conjugates market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Antibody Drug Conjugates market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cancer Antibody Drug Conjugates market is segmented into
First & Second Generation ADCs
Third Generation ADCs
Segment by Application, the Cancer Antibody Drug Conjugates market is segmented into
Hospitals
Clinics
Other
The Cancer Antibody Drug Conjugates market is analysed and market size information is provided by regions (countries). Segment by Application, the Cancer Antibody Drug Conjugates market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Antibody Drug Conjugates Market Share Analysis
Cancer Antibody Drug Conjugates market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Antibody Drug Conjugates business, the date to enter into the Cancer Antibody Drug Conjugates market, Cancer Antibody Drug Conjugates product introduction, recent developments, etc.
The major vendors covered:
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
レポート目次Table of Contents
1 Cancer Antibody Drug Conjugates Market Overview
1.1 Cancer Antibody Drug Conjugates Product Scope
1.2 Cancer Antibody Drug Conjugates Segment by Type
1.2.1 Global Cancer Antibody Drug Conjugates Sales by Type (2020-2026)
1.2.2 First & Second Generation ADCs
1.2.3 Third Generation ADCs
1.3 Cancer Antibody Drug Conjugates Segment by Application
1.3.1 Global Cancer Antibody Drug Conjugates Sales Comparison by Application (2020-2026)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Cancer Antibody Drug Conjugates Market Estimates and Forecasts (2015-2026)
1.4.1 Global Cancer Antibody Drug Conjugates Sales Growth Rate (2015-2026)
1.4.2 Global Cancer Antibody Drug Conjugates Revenue and Growth Rate (2015-2026)
1.4.3 Global Cancer Antibody Drug Conjugates Price Trends (2015-2026)
2 Cancer Antibody Drug Conjugates Estimate and Forecast by Region
2.1 Global Cancer Antibody Drug Conjugates Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Cancer Antibody Drug Conjugates Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2015-2020)
2.2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2015-2020)
2.3 Global Cancer Antibody Drug Conjugates Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Cancer Antibody Drug Conjugates Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
2.4.2 Europe Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
2.4.3 China Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
2.4.4 Japan Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
2.4.6 India Cancer Antibody Drug Conjugates Estimates and Projections (2015-2026)
3 Global Cancer Antibody Drug Conjugates Competition Landscape by Players
3.1 Global Top Cancer Antibody Drug Conjugates Players by Sales (2015-2020)
3.2 Global Top Cancer Antibody Drug Conjugates Players by Revenue (2015-2020)
3.3 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Antibody Drug Conjugates as of 2019)
3.4 Global Cancer Antibody Drug Conjugates Average Price by Company (2015-2020)
3.5 Manufacturers Cancer Antibody Drug Conjugates Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Cancer Antibody Drug Conjugates Players (Opinion Leaders)
4 Global Cancer Antibody Drug Conjugates Market Size by Type
4.1 Global Cancer Antibody Drug Conjugates Historic Market Review by Type (2015-2020)
4.1.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
4.1.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2015-2020)
4.1.3 Global Cancer Antibody Drug Conjugates Price by Type (2014-2020)
4.2 Global Cancer Antibody Drug Conjugates Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Type (2021-2026)
4.2.3 Global Cancer Antibody Drug Conjugates Price Forecast by Type (2021-2026)
5 Global Cancer Antibody Drug Conjugates Market Size by Application
5.1 Global Cancer Antibody Drug Conjugates Historic Market Review by Application (2015-2020)
5.1.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
5.1.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2015-2020)
5.1.3 Global Cancer Antibody Drug Conjugates Price by Application (2015-2020)
5.2 Global Cancer Antibody Drug Conjugates Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Antibody Drug Conjugates Price Forecast by Application (2021-2026)
3 North America Cancer Antibody Drug Conjugates Market Facts & Figures
3.2 North America Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
3.3 North America Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
3.4 North America Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
4 Europe Cancer Antibody Drug Conjugates Market Facts & Figures
4.2 Europe Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
4.3 Europe Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
4.4 Europe Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
5 China Cancer Antibody Drug Conjugates Market Facts & Figures
5.2 China Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
5.3 China Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
5.4 China Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
6 Japan Cancer Antibody Drug Conjugates Market Facts & Figures
6.2 Japan Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
6.3 Japan Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
6.4 Japan Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
7 Southeast Asia Cancer Antibody Drug Conjugates Market Facts & Figures
7.2 Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
8 India Cancer Antibody Drug Conjugates Market Facts & Figures
8.2 India Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
8.3 India Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
8.4 India Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Cancer Antibody Drug Conjugates Business
12.1 Novartis
12.1.1 Novartis Cancer Antibody Drug Conjugates Corporation Information
12.1.2 Novartis Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
12.1.5 Novartis Recent Development
12.2 Merck
12.2.1 Merck Cancer Antibody Drug Conjugates Corporation Information
12.2.2 Merck Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck Cancer Antibody Drug Conjugates Products Offered
12.2.5 Merck Recent Development
12.3 Roche
12.3.1 Roche Cancer Antibody Drug Conjugates Corporation Information
12.3.2 Roche Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Roche Cancer Antibody Drug Conjugates Products Offered
12.3.5 Roche Recent Development
12.4 AbbVie
12.4.1 AbbVie Cancer Antibody Drug Conjugates Corporation Information
12.4.2 AbbVie Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.4.4 AbbVie Cancer Antibody Drug Conjugates Products Offered
12.4.5 AbbVie Recent Development
12.5 UCB
12.5.1 UCB Cancer Antibody Drug Conjugates Corporation Information
12.5.2 UCB Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.5.4 UCB Cancer Antibody Drug Conjugates Products Offered
12.5.5 UCB Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Corporation Information
12.6.2 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Products Offered
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Stem CentRx
12.7.1 Stem CentRx Cancer Antibody Drug Conjugates Corporation Information
12.7.2 Stem CentRx Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Stem CentRx Cancer Antibody Drug Conjugates Products Offered
12.7.5 Stem CentRx Recent Development
12.8 Biogen Idec
12.8.1 Biogen Idec Cancer Antibody Drug Conjugates Corporation Information
12.8.2 Biogen Idec Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Biogen Idec Cancer Antibody Drug Conjugates Products Offered
12.8.5 Biogen Idec Recent Development
12.9 Nordic Nanovector
12.9.1 Nordic Nanovector Cancer Antibody Drug Conjugates Corporation Information
12.9.2 Nordic Nanovector Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Products Offered
12.9.5 Nordic Nanovector Recent Development
12.10 Millennium
12.10.1 Millennium Cancer Antibody Drug Conjugates Corporation Information
12.10.2 Millennium Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Millennium Cancer Antibody Drug Conjugates Products Offered
12.10.5 Millennium Recent Development
12.11 Biotest AG
12.11.1 Biotest AG Cancer Antibody Drug Conjugates Corporation Information
12.11.2 Biotest AG Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Biotest AG Cancer Antibody Drug Conjugates Products Offered
12.11.5 Biotest AG Recent Development
12.12 PDL BioPharma
12.12.1 PDL BioPharma Cancer Antibody Drug Conjugates Corporation Information
12.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Products Offered
12.12.5 PDL BioPharma Recent Development
12.13 Progenics Pharmaceuticals
12.13.1 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Corporation Information
12.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Products Offered
12.13.5 Progenics Pharmaceuticals Recent Development
12.14 Seattle Genetics
12.14.1 Seattle Genetics Cancer Antibody Drug Conjugates Corporation Information
12.14.2 Seattle Genetics Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Products Offered
12.14.5 Seattle Genetics Recent Development
12.15 Viventia Biotechnologies
12.15.1 Viventia Biotechnologies Cancer Antibody Drug Conjugates Corporation Information
12.15.2 Viventia Biotechnologies Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Products Offered
12.15.5 Viventia Biotechnologies Recent Development
12.16 AbGenomics Corporation
12.16.1 AbGenomics Corporation Cancer Antibody Drug Conjugates Corporation Information
12.16.2 AbGenomics Corporation Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Products Offered
12.16.5 AbGenomics Corporation Recent Development
12.17 Helix BioPharma
12.17.1 Helix BioPharma Cancer Antibody Drug Conjugates Corporation Information
12.17.2 Helix BioPharma Cancer Antibody Drug Conjugates Business Overview and Total Revenue
12.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Products Offered
12.17.5 Helix BioPharma Recent Development
13 Cancer Antibody Drug Conjugates Manufacturing Cost Analysis
13.1 Cancer Antibody Drug Conjugates Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Cancer Antibody Drug Conjugates
13.4 Cancer Antibody Drug Conjugates Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Cancer Antibody Drug Conjugates Distributors List
14.3 Cancer Antibody Drug Conjugates Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
List of TablesTable 1. Global Cancer Antibody Drug Conjugates Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Cancer Antibody Drug Conjugates Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Cancer Antibody Drug Conjugates Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Cancer Antibody Drug Conjugates Sales (K Pcs) by Region (2015-2020)
Table 5. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2015-2020)
Table 6. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Cancer Antibody Drug Conjugates Revenue Share by Region (2015-2020)
Table 8. Global Cancer Antibody Drug Conjugates Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Cancer Antibody Drug Conjugates Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Cancer Antibody Drug Conjugates Revenue Share Forecast by Region (2021-2026)
Table 12. Global Cancer Antibody Drug Conjugates (K Pcs) of Key Companies (2015-2020)
Table 13. Global Cancer Antibody Drug Conjugates Sales Share by Company (2015-2020)
Table 14. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Cancer Antibody Drug Conjugates Revenue Share by Company (2015-2020)
Table 16. Global Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Antibody Drug Conjugates as of 2019)
Table 17. Global Cancer Antibody Drug Conjugates Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Cancer Antibody Drug Conjugates Manufacturing Sites and Area Served
Table 19. Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Cancer Antibody Drug Conjugates Players
Table 22. Global Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 23. Global Cancer Antibody Drug Conjugates Sales Share by Type (2015-2020)
Table 24. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Cancer Antibody Drug Conjugates Price (K Pcs) by Type (2015-2020)
Table 26. Global Cancer Antibody Drug Conjugates Sales Share by Type (2021-2026)
Table 27. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Cancer Antibody Drug Conjugates Revenue Share by Type (2021-2026)
Table 29. Global Cancer Antibody Drug Conjugates Price (K Pcs) by Type (2021-2026)
Table 30. Global Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 31. Global Cancer Antibody Drug Conjugates Sales Share by Application (2015-2020)
Table 32. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Cancer Antibody Drug Conjugates Price (K Pcs) by Application (2015-2020)
Table 34. Global Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2021-2026)
Table 35. Global Cancer Antibody Drug Conjugates Sales Share by Application (2021-2026)
Table 36. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Cancer Antibody Drug Conjugates Revenue Share by Application (2021-2026)
Table 38. Global Cancer Antibody Drug Conjugates Price (K Pcs) by Application (2021-2026)
Table 39. United States Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 40. United States Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 41. United States Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 42. United States Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 43. United States Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 44. United States Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
Table 45. Europe Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 47. Europe Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 49. Europe Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 51. China Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 52. China Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 53. China Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 54. China Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 55. China Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 56. China Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
Table 57. Japan Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 59. Japan Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 61. Japan Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
Table 69. India Cancer Antibody Drug Conjugates Sales (K Pcs) by Company (2015-2020)
Table 70. India Cancer Antibody Drug Conjugates Sales Market Share by Company (2015-2020)
Table 71. India Cancer Antibody Drug Conjugates Sales (K Pcs) by Type (2015-2020)
Table 72. India Cancer Antibody Drug Conjugates Sales Market Share by Type (2015-2020)
Table 73. India Cancer Antibody Drug Conjugates Sales (K Pcs) by Application (2015-2020)
Table 74. India Cancer Antibody Drug Conjugates Sales Market Share by Application (2015-2020)
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Novartis Cancer Antibody Drug Conjugates Product
Table 79. Novartis Recent Development
Table 80. Merck Corporation Information
Table 81. Merck Description and Business Overview
Table 82. Merck Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Merck Cancer Antibody Drug Conjugates Product
Table 84. Merck Recent Development
Table 85. Roche Corporation Information
Table 86. Roche Description and Business Overview
Table 87. Roche Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Roche Cancer Antibody Drug Conjugates Product
Table 89. Roche Recent Development
Table 90. AbbVie Corporation Information
Table 91. AbbVie Description and Business Overview
Table 92. AbbVie Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. AbbVie Cancer Antibody Drug Conjugates Product
Table 94. AbbVie Recent Development
Table 95. UCB Corporation Information
Table 96. UCB Description and Business Overview
Table 97. UCB Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. UCB Cancer Antibody Drug Conjugates Product
Table 99. UCB Recent Development
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product
Table 104. Bristol-Myers Squibb Recent Development
Table 105. Stem CentRx Corporation Information
Table 106. Stem CentRx Description and Business Overview
Table 107. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Stem CentRx Cancer Antibody Drug Conjugates Product
Table 109. Stem CentRx Recent Development
Table 110. Biogen Idec Corporation Information
Table 111. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Biogen Idec Description and Business Overview
Table 113. Biogen Idec Cancer Antibody Drug Conjugates Product
Table 114. Biogen Idec Recent Development
Table 115. Nordic Nanovector Corporation Information
Table 116. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Nordic Nanovector Description and Business Overview
Table 118. Nordic Nanovector Cancer Antibody Drug Conjugates Product
Table 119. Nordic Nanovector Recent Development
Table 120. Millennium Corporation Information
Table 121. Millennium Description and Business Overview
Table 122. Millennium Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Millennium Cancer Antibody Drug Conjugates Product
Table 124. Millennium Recent Development
Table 125. Biotest AG Corporation Information
Table 126. Biotest AG Description and Business Overview
Table 127. Biotest AG Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Biotest AG Cancer Antibody Drug Conjugates Product
Table 129. Biotest AG Recent Development
Table 130. PDL BioPharma Corporation Information
Table 131. PDL BioPharma Description and Business Overview
Table 132. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. PDL BioPharma Cancer Antibody Drug Conjugates Product
Table 134. PDL BioPharma Recent Development
Table 135. Progenics Pharmaceuticals Corporation Information
Table 136. Progenics Pharmaceuticals Description and Business Overview
Table 137. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product
Table 139. Progenics Pharmaceuticals Recent Development
Table 140. Seattle Genetics Corporation Information
Table 141. Seattle Genetics Description and Business Overview
Table 142. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Seattle Genetics Cancer Antibody Drug Conjugates Product
Table 144. Seattle Genetics Recent Development
Table 145. Viventia Biotechnologies Corporation Information
Table 146. Viventia Biotechnologies Description and Business Overview
Table 147. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product
Table 149. Viventia Biotechnologies Recent Development
Table 150. AbGenomics Corporation Corporation Information
Table 151. AbGenomics Corporation Description and Business Overview
Table 152. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. AbGenomics Corporation Cancer Antibody Drug Conjugates Product
Table 154. AbGenomics Corporation Recent Development
Table 155. Helix BioPharma Corporation Information
Table 156. Helix BioPharma Description and Business Overview
Table 157. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 158. Helix BioPharma Cancer Antibody Drug Conjugates Product
Table 159. Helix BioPharma Recent Development
Table 160. Production Base and Market Concentration Rate of Raw Material
Table 161. Key Suppliers of Raw Materials
Table 162. Cancer Antibody Drug Conjugates Distributors List
Table 163. Cancer Antibody Drug Conjugates Customers List
Table 164. Market Key Trends
Table 165. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 166. Key Challenges
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Antibody Drug Conjugates Product Picture
Figure 2. Global Cancer Antibody Drug Conjugates Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Cancer Antibody Drug Conjugates Market Share by Application in 2020 & 2026
Figure 6. Hospitals Examples
Figure 7. Clinics Examples
Figure 8. Other Examples
Figure 9. Global Cancer Antibody Drug Conjugates Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Cancer Antibody Drug Conjugates Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Cancer Antibody Drug Conjugates Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Cancer Antibody Drug Conjugates Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Cancer Antibody Drug Conjugates Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Cancer Antibody Drug Conjugates Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Cancer Antibody Drug Conjugates Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Cancer Antibody Drug Conjugates Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Cancer Antibody Drug Conjugates Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Cancer Antibody Drug Conjugates Players Market Share by Revenue in Cancer Antibody Drug Conjugates 2015 & 2019
Figure 27. Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Cancer Antibody Drug Conjugates Revenue Share by Type (2015-2020)
Figure 29. Global Cancer Antibody Drug Conjugates Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Cancer Antibody Drug Conjugates Revenue Share by Application (2015-2020)
Figure 31. Global Cancer Antibody Drug Conjugates Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 33. United States Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 34. Europe Cancer Antibody Drug Conjugates Sales Market Share by Company in 2019
Figure 35. Europe Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 36. Europe Cancer Antibody Drug Conjugates Sales Market Share by Application in 2019
Figure 37. China Cancer Antibody Drug Conjugates Sales Market Share by Company in 2019
Figure 38. China Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 39. China Cancer Antibody Drug Conjugates Sales Market Share by Application in 2019
Figure 40. Japan Cancer Antibody Drug Conjugates Sales Market Share by Company in 2019
Figure 41. Japan Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 42. Japan Cancer Antibody Drug Conjugates Sales Market Share by Application in 2019
Figure 43. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Company in 2019
Figure 44. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 45. Southeast Asia Cancer Antibody Drug Conjugates Sales Market Share by Application in 2019
Figure 46. India Cancer Antibody Drug Conjugates Sales Market Share by Company in 2019
Figure 47. India Cancer Antibody Drug Conjugates Sales Market Share by Type in 2019
Figure 48. India Cancer Antibody Drug Conjugates Sales Market Share by Application in 2019
Figure 49. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. UCB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Stem CentRx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Biogen Idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Nordic Nanovector Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Millennium Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Biotest AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. PDL BioPharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Progenics Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Viventia Biotechnologies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. AbGenomics Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Helix BioPharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Key Raw Materials Price Trend
Figure 67. Manufacturing Cost Structure of Cancer Antibody Drug Conjugates
Figure 68. Manufacturing Process Analysis of Cancer Antibody Drug Conjugates
Figure 69. Cancer Antibody Drug Conjugates Industrial Chain Analysis
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
Figure 72. Porter's Five Forces Analysis
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
抗体薬物複合体の世界市場レポート2020 Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased…- 濾胞甲状腺がん治療薬の世界市場レポート2020 Market Analysis and Insights: Global Follicular Thyroid Cancer Drug Market The global Follicular Thyroid Cancer Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Follicular Thyroid Cancer Drug Scope an…
- 上咽頭癌治療薬の世界市場レポート2020 Market Analysis and Insights: Global Nasopharyngeal Cancer Drug Market The global Nasopharyngeal Cancer Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Nasopharyngeal Cancer Drug Scope and Market Siz…
- 小分子がん治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Small Molecule Cancer Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Small Molecule Can…
- CD抗原がん治療の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global CD Antigen Cancer Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The CD Antigen Cancer T…